Paul Graves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Graves has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Christopher S. Rabender
5 shared publicationsGobalakrishnan Sundaresan
5 shared publications- Jamal Zweit
Department of Radiology, Center for Molecular Imaging, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
5 shared publications - Nitai D. Mukhopadhyay
Department of Biostatistics Virginia Commonwealth University Richmond Virginia USA
5 shared publications - Robert J. Cardnell
Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 1
5 shared publications - Ross B. Mikkelsen
Department of Radiation Oncology, Massey Comprehensive Cancer Center, Virginia Commonwealth University
5 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Novel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- 16 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel ClpP Activators Stimulate ALAS1 Degradation and Inhibition of Heme Synthesis
The porphyrias are rare, inherited disorders caused by defects in enzymes of the heme biosynthetic pathway. These deficiencies can result in inefficient heme synthesis and the pathological buildup of toxic intermediates such as 5-aminolevulinic acid (5-ALA) and porphobilinogen (PBG). In hepatic tissues, mitochondrial ALAS1 serves as the first and rate-limiting enzyme in heme biosynthesis; increased expression of ALAS1 by environmental factors contributes to the pathology of acute hepatic porphyria (AHP). Conversely, siRNA-mediated silencing (e.g., Givlaari®) reduces ALAS1 expression and the toxic accumulation of 5-ALA and PBG, validating ALAS1 as a clinical target for AHP. Recently, we identified a class of small molecules that rapidly promote ALAS1 degradation. One of these compounds, ONC201 (dordaviprone, Modeyso®), is an orally available small molecule recently approved by the FDA for the treatment of glioma. We previously showed that ONC201 and related compounds (TR-107, TR-57) activate the mitochondrial matrix protease ClpP in a highly selective manner (hereafter, ClpP agonists). In this study, we demonstrate that ALAS1 is robustly degraded in hepatic and erythroleukemia models in a time-, dose-, and ClpP-dependent manner as confirmed by Western blotting. In parallel with loss of ALAS1, we detected a rapid decline in ClpX, a subunit of ClpXP and proposed regulator of ALAS1. Concomitant with ALAS1 degradation, we observed inhibition of 5-ALA and PBG formation and heme synthesis, demonstrating direct pathway modulation. Importantly, these studies suggest that ClpP agonists are effective small molecules for the reduction of ALAS1 and toxic heme pathway intermediates. In summary, these studies position ClpP agonists, originally developed as anti-cancer agents, as potentially new and fast-acting oral therapeutics for the treatment of acute hepatic porphyrias.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figures Collated from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figures Collated from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression
- Open Access
- 25 April 2019
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 14 (5) , 1020-1029
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
ONC201 is a first-in-class imipridone molecule currently in clinical trials for the treatment of multiple cancers. Despite enormous clinical potential, the mechanism of action is controversial. To investigate the mechanism of ONC201 and identify compounds with improved potency, we tested a series of novel ONC201 analogs (TR compounds) for effects on cell viability and stress responses in breast and other cancer models. The TR compounds were found to be ~50-100 times more potent at inhibiting cell proliferation and inducing the integrated stress response (ISR) protein ATF4 than ONC201. Using immobilized TR compounds, we identified the human mitochondrial caseinolytic protease P (ClpP) as a specific binding protein by mass spectrometry. Affinity chromatography/drug competition assays showed that the TR compounds bound ClpP with ~10 fold higher affinity compared to ONC201. Importantly, we found that the peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compounds in a dose- and time-dependent manner, with the TR compounds displaying a ~10-100 fold increase in potency over ONC201. Finally, siRNA knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compounds including induction of CHOP, loss of the mitochondrial proteins (TFAM, TUFM) and the cytostatic effects of these compounds. Thus, we report that ClpP directly binds ONC201 and the related TR compounds, and is an important biological target for this class of molecules. Moreover, these studies provide for the first time, a biochemical basis for the difference in efficacy between ONC201 and the TR compounds.
- 25 April 2019
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 14 (5) , 1020-1029
Open AccessMitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
ONC201 is a first-in-class imipridone molecule currently in clinical trials for the treatment of multiple cancers. Despite enormous clinical potential, the mechanism of action is controversial. To investigate the mechanism of ONC201 and identify compounds with improved potency, we tested a series of novel ONC201 analogs (TR compounds) for effects on cell viability and stress responses in breast and other cancer models. The TR compounds were found to be ~50-100 times more potent at inhibiting cell proliferation and inducing the integrated stress response (ISR) protein ATF4 than ONC201. Using immobilized TR compounds, we identified the human mitochondrial caseinolytic protease P (ClpP) as a specific binding protein by mass spectrometry. Affinity chromatography/drug competition assays showed that the TR compounds bound ClpP with ~10 fold higher affinity compared to ONC201. Importantly, we found that the peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compounds in a dose- and time-dependent manner, with the TR compounds displaying a ~10-100 fold increase in potency over ONC201. Finally, siRNA knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compounds including induction of CHOP, loss of the mitochondrial proteins (TFAM, TUFM) and the cytostatic effects of these compounds. Thus, we report that ClpP directly binds ONC201 and the related TR compounds, and is an important biological target for this class of molecules. Moreover, these studies provide for the first time, a biochemical basis for the difference in efficacy between ONC201 and the TR compounds.